查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012870

生物保存市场：2026-2032年全球市场预测（按产品类型、技术、检体类型、应用和最终用户划分）

Biopreservation Market by Product Type, Technology, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，生物保存市场价值将达到 45.7 亿美元，到 2026 年将成长到 57.3 亿美元，到 2032 年将达到 261.1 亿美元，复合年增长率为 28.26%。

主要市场统计数据
基准年 2025 45.7亿美元
预计年份：2026年 57.3亿美元
预测年份 2032 261.1亿美元
复合年增长率 (%) 28.26%

生物保存已从单纯的实验室便利措施发展成为支撑现代医疗保健、先进治疗方法和生命科学研究的关键职能。细胞和基因疗法的进步、器官和组织库的扩展以及复杂生物製药的全球开发，都促使人们对可靠的生物材料长期保存的需求日益增长。同时，低温工程、保存化学品和数位监测技术的进步，使得高度可靠的保存在技术上成为可能，同时也提高了采购、法规遵循和员工能力的要求。

在实践中，各机构面临多重挑战：将各种保存技术整合到端到端的工作流程中，管理专用耗材和设备的库存，以及在日益全球化的供应链中维护低温运输的完整性。这些压力与改善治疗效果、减少废弃物和拓展临床服务范围的机会并存。因此，领导者必须权衡短期营运决策与策略投资，以实现可扩展的保存能力，同时确保管治架构符合不断变化的监管和认证要求。

本文旨在引出一项高阶审查，该审查将探讨技术转折点、政策驱动因素、商业性压力以及各组织可采取的实际措施，以加强其保护策略。文章也强调，临床团队、供应链管理人员以及研发团队之间需要进行跨职能合作，才能将保育科学转化为可靠且可重复的实践。最终，协作方式将决定哪些机构能够永续地支持下一代治疗方法、拓展捐赠项目，并降低与供应中断和合规性缺陷相关的风险。

生物保存技术、监管预期和商业化途径的变革性变化正在重新定义生物材料的保存和利用方式。

生物保存领域正经历一场变革，其驱动力来自于技术进步、日益严格的监管以及不断演进的商业化模式。诸如玻璃化冷冻和改良的冷冻干燥等新型保存技术正在挑战传统的低温运输模式，而即时监控和物联网赋能的储存系统则提高了人们对资料连续性和可追溯性的期望。这些创新并非孤立事件，而是正在重塑企业设计储存设施、培养人才以及与供应商建立关係的方式。

2025 年美国关税对生物保存供应链、试剂采购、设备采购及跨境临床物流的累积影响。

2025年实施的关税调整为全球生物保存价值链增添了新的复杂性，影响了关键试剂、专用耗材和昂贵设备的采购成本。这种累积影响贯穿整个采购週期，各机构都在重新审视其供应商组合、规划库存缓衝，并权衡进口的累积到岸成本与区域采购方案。对于一些机构而言，这种关税环境加速了将生产迁回本国、建立区域分销中心以及优先考虑多元化采购策略以增强自身韧性的讨论。

将产品类型、保存技术、检体分类、应用和最终用户趋势与策略部署模式连结起来的关键细分洞察。

为了整体情况了解生物保存，必须综合考虑产品类型、保存技术、各种样本分类、临床和研究应用以及最终用户行为。从产品角度来看，产品系列分为耗材与设备。耗材包括冷冻保护剂、培养基、管瓶和试管。在冷冻保护剂中，二甲基亚砜(DMSO) 和甘油仍然是细胞和组织研究中的主要化学品，其选择基于其适用性以及下游製程要求。设备组合包括低温冷冻库、监控系统和储存系统，其选择取决于处理能力需求、验证预期以及与设施环境控制系统的整合。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和战略考虑因素，这些因素推动了招聘、投资和政策协调。

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的生物保存优先事项、投资模式和监管合作产生显着影响。在美洲，完善的临床基础设施、不断扩展的细胞和基因治疗产品线以及整合的商业管道正在推动对高通量低温设备和经验证耗材的需求。同时，法律规范强调可追溯性和品管体系，为提供可扩展解决方案和服务模式、并能提供快速验证支援的机构投资者创造了极具吸引力的环境。

竞争格局和企业级策略洞察，重点在于伙伴关係、产品系列、製造地和创新管道。

在生物保存领域，企业策略正日益融合产品创新、垂直整合和服务主导交付，以在技术先进的环境中脱颖而出。主要企业正致力于提供端到端解决方案，整合耗材、经过经验的仪器和资料丰富的监测平台，从而减轻临床和科学研究客户的整合负担。耗材製造商和仪器供应商之间的策略伙伴关係也日趋普遍，从而能够提供捆绑式解决方案，简化验证和采购流程。

为行业领导者提供切实可行的建议，以加速韧性建设，降低价值链风险，并在治疗、临床和研究领域创造价值。

产业领导者应采取一系列综合倡议，以增强韧性、释放价值并支援保存解决方案的可扩展部署。首先，应召集采购和临床相关人员，制定统一规范，优先考虑互通性、资料完整性和易于检验。这将减少产品合格中的摩擦，并缩短部署时间。其次，应实现供应商网路多元化，并纳入能够提供现场组装、检验支援和快速物流响应的本地合作伙伴和服务供应商，以降低跨境关税波动和运输中断带来的风险。

本文檔概述了一种透明的调查方法，详细说明了资料来源、检验协议、专家合作以及用于确保可靠见解的分析框架。

本研究采用综合分析调查方法，该方法着重于专家访谈、精心挑选的技术文献以及检验的供应商文件。关键资讯来源包括与临床和供应链负责人进行结构化访谈、与设备和耗材製造商进行技术简报，以及与法规事务专家进行咨询，以确保对合规要求进行切实可行的解读。这些定性研究结果与技术标准、产品规格和已发布的方法检验指南进行交叉比对，以验证操作和性能声明的一致性。

结论：整合临床、商业和研究生态系统中相关人员的策略意义、新兴风险和短期优先事项。

总之，生物保存领域正处于科学创新、营运严谨性和供应链复杂性的交会点。保存化学和储存技术的进步为拓展临床项目和引入先进治疗方法创造了新的机会，而监管和商业性压力正在重塑采购和验证的优先事项。这些因素共同推动着向整合解决方案的转变，这些解决方案强调互通性、资料连续性和弹性采购。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：生物保存市场：依产品类型划分

  • 消耗品
    • 防冻剂
      • DMSO
      • 甘油
    • 培养基
    • 管瓶管
  • 装置
    • 超低温冷冻柜
    • 监控系统
    • 储存系统

第九章：生物保存市场：依技术划分

  • 冷冻保存
  • 冷藏
  • 冷冻干燥
  • 玻璃化

第 10 章：检体类型分類的生物保存市场

  • 生物液体
  • 血液成分
  • 细胞
  • 器官
  • 组织

第 11 章：生物保存市场：依应用分类

  • 辅助生殖技术
  • 血液保存
  • 细胞疗法
  • 器官保存
  • 组织工程

第十二章：生物保存市场：依最终使用者划分

  • 血库
  • 不孕症治疗诊所
  • 医院和诊所
  • 製药和生物技术公司
  • 研究机构

第 13 章：生物保存市场：按地区

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：生物保存市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 生物保存市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国生物保存市场

第十七章：中国生物保存市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Avantor, Inc.
  • Azenta, Inc.
  • Bio-Techne Corporation
  • BioCision LLC
  • BioLife Solutions, Inc.
  • Biomatrica, Inc.
  • Cryoport, Inc.
  • LabVantage Solutions, Inc.
  • Merck KGaA
  • MVE Biological Solutions
  • Panasonic Corporation
  • PHC Holdings Corporation
  • PrincetonCryo
  • Sartorius AG
  • Stirling Ultracold
  • Taylor-Wharton
  • Thermo Fisher Scientific Inc.
  • ThermoGenesis Holdings, Inc.
  • VWR International, LLC
  • X-Therma, Inc.
Product Code: MRR-437D45957B50

The Biopreservation Market was valued at USD 4.57 billion in 2025 and is projected to grow to USD 5.73 billion in 2026, with a CAGR of 28.26%, reaching USD 26.11 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.57 billion
Estimated Year [2026] USD 5.73 billion
Forecast Year [2032] USD 26.11 billion
CAGR (%) 28.26%

Biopreservation has evolved from a laboratory convenience to a mission-critical capability underpinning modern healthcare delivery, advanced therapeutics, and life sciences research. Advances in cell and gene therapies, expanded organ and tissue banking initiatives, and the global roll-out of complex biologics have together increased the operational imperative to preserve biological materials reliably over extended periods. Concurrently, improvements in cryogenic engineering, preservation chemistries, and digital monitoring have made high-integrity storage more technically achievable, yet have also raised the bar for procurement, regulatory compliance, and workforce competency.

In practice, organizations face a multifaceted set of challenges: integrating diverse preservation technologies into end-to-end workflows, managing specialized consumable and equipment inventories, and maintaining cold chain integrity across increasingly international supply routes. These pressures coexist with opportunities to enhance therapeutic outcomes, reduce waste, and extend the reach of clinical services. As a result, leaders must balance near-term operational choices with strategic investments that enable scalable preservation capabilities, while ensuring governance frameworks meet evolving regulatory and accreditation expectations.

This introduction sets the stage for an executive-level synthesis that examines technological inflection points, policy drivers, commercial pressures, and practical steps organizations can apply to fortify their preservation strategies. It underscores the need for cross-functional alignment among clinical teams, supply chain managers, and R&D groups to translate preservation science into reliable, reproducible practice. Ultimately, a coordinated approach will determine which institutions can sustainably support next-generation therapies, expand donor programs, and mitigate risks tied to supply disruptions and compliance gaps.

Transformative shifts in biopreservation technology, regulatory expectations, and commercialization pathways redefining how biological materials are preserved and mobilized

The landscape of biopreservation is undergoing transformative shifts driven by converging technological advances, regulatory intensification, and evolving commercialization models. Emerging preservation methods such as vitrification and refined lyophilization techniques are challenging legacy cold chain paradigms, while real-time monitoring and IoT-enabled storage systems are elevating expectations for data continuity and traceability. These innovations are not isolated; they are reshaping how organizations design storage facilities, train personnel, and negotiate supplier relationships.

At the same time, regulatory bodies worldwide are tightening oversight of biologic handling, storage validation, and chain-of-custody documentation. This has prompted a move from ad hoc, lab-level practices to formalized quality management systems encompassing calibration protocols, environmental monitoring, and documented contingency plans. Commercial pressures are also reshaping the market: as cell and gene therapies move from clinical trials into broader commercialization, the need for scalable, validated preservation solutions has accelerated. Manufacturers of consumables and equipment are responding with modular, interoperable offerings designed to reduce integration friction and shorten validation timelines.

These shifts create both complexity and opportunity. Organizations that proactively adopt interoperable systems, implement robust digital traceability, and align procurement with regulatory expectations can reduce operational risk and speed time-to-treatment. Conversely, institutions that lag in adoption risk increased spoilage, audit findings, and constrained access to emerging therapies. In short, the landscape is moving from discrete products toward systems-oriented solutions that require cross-functional coordination and strategic investment.

Cumulative impact of United States tariffs in 2025 on biopreservation supply chains, reagent sourcing, equipment procurement, and cross-border clinical logistics

Tariff changes implemented in 2025 introduced a new layer of complexity to global biopreservation supply chains, affecting the sourcing economics for critical reagents, specialized consumables, and high-value equipment. The cumulative effects are noticeable across procurement cycles as organizations reassess supplier portfolios, plan inventory buffers, and evaluate the total landed cost of imports versus regional sourcing options. For some institutions, the tariff environment has accelerated conversations about reshoring production, establishing regional distribution hubs, and prioritizing multi-sourcing strategies to strengthen resilience.

Operationally, increased import duties on equipment and consumables have translated into longer procurement lead times and higher capital outlays for facility upgrades. Procurement and finance leaders have responded by renegotiating supplier contracts, seeking longer-term purchase agreements that include price protection clauses, and evaluating leasing or service-based models to mitigate upfront capital burdens. For suppliers, tariffs have encouraged strategic decisions including local assembly, expanded distributor networks, and targeted investments in markets where demand is both material and stable.

Clinically, tariffs can indirectly affect access by shifting the economics of advanced therapies and specialized preservation workflows, prompting healthcare systems to prioritize interventions where preservation costs can be justified by clinical value. From a risk perspective, organizations must now account for tariff volatility in contingency planning, stress-test their supplier ecosystems, and maintain transparent documentation to support customs and regulatory inquiries. In this environment, strategic procurement, rigorous supplier qualification, and flexible logistics planning become essential components of operational continuity.

Key segmentation insights linking product types, preservation technologies, sample classes, applications, and end-user dynamics to strategic adoption patterns

Understanding the biopreservation landscape requires an integrated view of product typologies, preservation technologies, the array of sample classes, clinical and research applications, and end-user behaviors. From a product perspective, offerings split into consumables and equipment, with consumables encompassing cryoprotectants, media, and vials and tubes. Within cryoprotectants, dimethyl sulfoxide (DMSO) and glycerol remain dominant chemistries for cell and tissue work, each selected based on compatibility profiles and downstream application requirements. Equipment portfolios cover cryogenic freezers, monitoring systems, and storage systems, and their selection depends on throughput needs, validation expectations, and integration with facility environmental controls.

Technology choices shape operational design. Cryopreservation, hypothermic storage, lyophilization, and vitrification offer distinct trade-offs in complexity, stability, and suitability for different biological materials. Cryopreservation and hypothermic storage are commonly used for cells and blood components, while lyophilization and vitrification are increasingly considered for specialized tissue products and certain biological fluids where ambient stability or reduced cold chain dependence is advantageous. Each technology choice has downstream implications for training, validation, and quality oversight.

Sample type considerations further refine procurement and operational priorities. Biological fluids, blood components, cells, organs, and tissues present unique handling, containment, and potency-preservation requirements that inform both consumable selection and equipment sizing. Applications-ranging from assisted reproductive technology and blood preservation to cell therapy, organ preservation, and tissue engineering-drive specific performance attributes for products and technologies. Finally, end users such as blood banks, fertility clinics, hospitals and clinics, pharmaceutical and biotech companies, and research institutes differ in scale, regulatory rigor, and budgetary constraints, which in turn shape adoption pathways and supplier selection criteria. Integrating these segmentation lenses enables decision-makers to align technology investments with practical workflows, regulatory obligations, and strategic priorities.

Regional dynamics and strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that drive adoption, investment, and policy alignment

Regional dynamics significantly influence biopreservation priorities, investment patterns, and regulatory interactions across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, established clinical infrastructure, expanding cell and gene therapy pipelines, and integrated commercial channels drive demand for high-throughput cryogenic equipment and validated consumables, while regulatory frameworks emphasize traceability and quality systems. This creates an environment where scaled solutions and service models that offer rapid validation support are particularly attractive to institutional buyers.

Across Europe, Middle East & Africa, the interplay between stringent regulatory expectations and diverse healthcare delivery models results in a heterogeneous adoption landscape. High-regulation jurisdictions prioritize certified systems, thorough documentation, and interoperability with existing quality management systems, whereas markets with constrained infrastructure may favor solutions that reduce cold chain complexity, such as lyophilization or simplified storage workflows. In response, suppliers often pursue region-specific validation packages and collaborate with local distributors to navigate varied procurement and compliance environments.

Asia-Pacific presents a fast-growing demand profile driven by rising investments in biotech R&D, expanding manufacturing capabilities, and government support for advanced therapies. The diversity of the region means that some markets rapidly adopt cutting-edge preservation technologies, while others place emphasis on localized manufacturing and cost-effective consumables. Across all regions, cross-border regulatory harmonization efforts and supply chain localization trends shape supplier strategies, prompting partnerships, regional warehousing, and tailored service offerings to meet jurisdictional requirements and reduce lead times.

Competitive landscape and strategic company-level insights focusing on partnerships, product portfolios, manufacturing footprints, and innovation pipelines

Company strategies in the biopreservation space increasingly combine product innovation, vertical integration, and service-enabled offerings to differentiate in a technically demanding environment. Leading organizations pursue end-to-end solutions that integrate consumables, validated equipment, and data-rich monitoring platforms, thereby reducing the integration burden for clinical and research customers. Strategic partnerships between consumable manufacturers and equipment providers are becoming more common, enabling bundled solutions that simplify validation and procurement.

Manufacturers are investing in modular designs and interoperability standards to ease integration with facility management systems and to support remote monitoring and predictive maintenance. In parallel, contract manufacturers and specialized logistics providers are expanding capabilities to offer regional assembly, cold-chain last-mile services, and regulated storage hubs. These moves aim to shorten lead times and reduce the operational complexity that buyers face when managing multiple vendors across disparate geographies.

Additionally, companies are aligning product roadmaps with regulatory trends by embedding validation support, documentation packages, and training services into their commercial offerings. This approach helps customers accelerate implementation while meeting compliance obligations. Intellectual property strategies, targeted M&A to fill portfolio gaps, and investments in manufacturing redundancy are also evident, reflecting a prioritization of supply continuity and the ability to serve both clinical and research segments reliably.

Actionable recommendations for industry leaders to accelerate resilience, de-risk supply chains, and capture value across therapeutic, clinical, and research segments

Industry leaders should adopt an integrated set of actions that strengthen resilience, unlock value, and support scalable deployment of preservation solutions. First, align procurement and clinical stakeholders to create unified specifications that prioritize interoperability, data integrity, and ease of validation. Doing so reduces friction during product qualification and shortens implementation timelines. Second, diversify supplier networks to include regional partners and service providers capable of local assembly, validation support, and responsive logistics, thereby reducing exposure to cross-border tariff volatility and shipping disruptions.

Third, invest in digital monitoring and predictive maintenance to improve uptime and enable proactive quality management. These investments support regulatory documentation and reduce the likelihood of temperature excursions that can compromise biological materials. Fourth, structure commercial agreements to balance capital and operational expenditures; explore leasing, managed services, or bundled consumable agreements when capital constraints or tariff-driven cost increases are a concern. Fifth, embed training and change management into rollouts to ensure that staff competencies keep pace with technological complexity and validation obligations.

Finally, incorporate scenario-based contingency planning that explicitly models tariff impacts, supplier failure modes, and emergency transport routes. This will enable faster, evidence-based decisions when supply chain stressors materialize. Collectively, these actions will help organizations transition from reactive management to strategic stewardship of their preservation capabilities.

Transparent research methodology outlining data sources, validation protocols, expert engagements, and analytical frameworks used to ensure robust intelligence

This research synthesis is built on a multi-source methodology that emphasizes primary expert engagement, curated technical literature, and validated supplier documentation. Primary inputs included structured interviews with clinical and supply chain leaders, technical briefings with equipment and consumable manufacturers, and consultations with regulatory affairs specialists to ensure practical interpretation of compliance requirements. These qualitative insights were cross-referenced with technical standards, product specifications, and published method validation guidance to triangulate operational and performance claims.

Analytical protocols emphasized traceability and reproducibility. Claims about product capabilities and operational practices were validated against manufacturer technical sheets, peer-reviewed protocols where available, and documented real-world case examples. Expert reviewers provided context on adoption barriers, training needs, and validation timelines, which informed the recommendations and risk assessments. Data hygiene practices were applied to ensure that inputs were current, and any proprietary or vendor-supplied performance data were labeled and treated as conditional when not independently verified.

Limitations and caveats are clearly stated within the full deliverable, including areas where empirical evidence remains emergent or where regional regulatory interpretations diverge. The methodology balances depth of technical understanding with practical operational applicability, enabling decision-makers to apply the insights while acknowledging areas that warrant further localized validation or pilot testing.

Conclusion synthesizing strategic takeaways, emergent risks, and near-term priorities for stakeholders across clinical, commercial, and research ecosystems

In conclusion, the biopreservation domain sits at the intersection of scientific innovation, operational rigor, and supply chain complexity. Advances in preservation chemistries and storage technologies are creating new opportunities to expand clinical programs and enable advanced therapies, while regulatory and commercial pressures are reshaping procurement and validation priorities. The combined effect is a shift toward integrated solutions that emphasize interoperability, data continuity, and resilient sourcing.

Organizations that proactively recalibrate procurement strategies, invest in digital monitoring, and align cross-functional stakeholders will be best positioned to realize the clinical and operational benefits of modern preservation techniques. Conversely, those that defer strategic upgrades risk increased wastage, constrained clinical capacity, and difficulties meeting regulatory expectations. Near-term priorities should therefore focus on supplier diversification, targeted capital allocation for interoperability, and institutionalizing training and validation practices.

Overall, a pragmatic, systems-oriented approach that balances technology adoption with rigorous quality governance will enable healthcare providers, research organizations, and commercial developers to convert preservation science into dependable operational capability. Stakeholders should treat the insights provided here as a foundation for targeted pilots, procurement decisions, and policy engagement that together will shape the reliability and scalability of biopreservation services.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biopreservation Market, by Product Type

  • 8.1. Consumables
    • 8.1.1. Cryoprotectants
      • 8.1.1.1. DMSO
      • 8.1.1.2. Glycerol
    • 8.1.2. Media
    • 8.1.3. Vials & Tubes
  • 8.2. Equipment
    • 8.2.1. Cryogenic Freezers
    • 8.2.2. Monitoring Systems
    • 8.2.3. Storage Systems

9. Biopreservation Market, by Technology

  • 9.1. Cryopreservation
  • 9.2. Hypothermic Storage
  • 9.3. Lyophilization
  • 9.4. Vitrification

10. Biopreservation Market, by Sample Type

  • 10.1. Biological Fluids
  • 10.2. Blood Components
  • 10.3. Cells
  • 10.4. Organs
  • 10.5. Tissues

11. Biopreservation Market, by Application

  • 11.1. Assisted Reproductive Technology
  • 11.2. Blood Preservation
  • 11.3. Cell Therapy
  • 11.4. Organ Preservation
  • 11.5. Tissue Engineering

12. Biopreservation Market, by End User

  • 12.1. Blood Banks
  • 12.2. Fertility Clinics
  • 12.3. Hospitals & Clinics
  • 12.4. Pharmaceutical & Biotech Companies
  • 12.5. Research Institutes

13. Biopreservation Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biopreservation Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biopreservation Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Biopreservation Market

17. China Biopreservation Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Avantor, Inc.
  • 18.6. Azenta, Inc.
  • 18.7. Bio-Techne Corporation
  • 18.8. BioCision LLC
  • 18.9. BioLife Solutions, Inc.
  • 18.10. Biomatrica, Inc.
  • 18.11. Cryoport, Inc.
  • 18.12. LabVantage Solutions, Inc.
  • 18.13. Merck KGaA
  • 18.14. MVE Biological Solutions
  • 18.15. Panasonic Corporation
  • 18.16. PHC Holdings Corporation
  • 18.17. PrincetonCryo
  • 18.18. Sartorius AG
  • 18.19. Stirling Ultracold
  • 18.20. Taylor-Wharton
  • 18.21. Thermo Fisher Scientific Inc.
  • 18.22. ThermoGenesis Holdings, Inc.
  • 18.23. VWR International, LLC
  • 18.24. X-Therma, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPRESERVATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOPRESERVATION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOPRESERVATION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOPRESERVATION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOPRESERVATION MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPRESERVATION MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOPRESERVATION MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPRESERVATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOPRESERVATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPRESERVATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOPRESERVATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BIOPRESERVATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BIOPRESERVATION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOPRESERVATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOPRESERVATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOPRESERVATION MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOPRESERVATION MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOPRESERVATION MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOPRESERVATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOPRESERVATION MARKET SIZE, BY CRYOPROTECTANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOPRESERVATION MARKET SIZE, BY CRYOPROTECTANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOPRESERVATION MARKET SIZE, BY CRYOPROTECTANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOPRESERVATION MARKET SIZE, BY CRYOPROTECTANTS, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOPRESERVATION MARKET SIZE, BY DMSO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOPRESERVATION MARKET SIZE, BY DMSO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOPRESERVATION MARKET SIZE, BY DMSO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOPRESERVATION MARKET SIZE, BY GLYCEROL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOPRESERVATION MARKET SIZE, BY GLYCEROL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOPRESERVATION MARKET SIZE, BY GLYCEROL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOPRESERVATION MARKET SIZE, BY MEDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOPRESERVATION MARKET SIZE, BY MEDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOPRESERVATION MARKET SIZE, BY MEDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOPRESERVATION MARKET SIZE, BY VIALS & TUBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOPRESERVATION MARKET SIZE, BY VIALS & TUBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOPRESERVATION MARKET SIZE, BY VIALS & TUBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOPRESERVATION MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOPRESERVATION MARKET SIZE, BY EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOPRESERVATION MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOPRESERVATION MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOPRESERVATION MARKET SIZE, BY CRYOGENIC FREEZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOPRESERVATION MARKET SIZE, BY CRYOGENIC FREEZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOPRESERVATION MARKET SIZE, BY CRYOGENIC FREEZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOPRESERVATION MARKET SIZE, BY MONITORING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOPRESERVATION MARKET SIZE, BY MONITORING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOPRESERVATION MARKET SIZE, BY MONITORING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOPRESERVATION MARKET SIZE, BY STORAGE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOPRESERVATION MARKET SIZE, BY STORAGE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOPRESERVATION MARKET SIZE, BY STORAGE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOPRESERVATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOPRESERVATION MARKET SIZE, BY CRYOPRESERVATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOPRESERVATION MARKET SIZE, BY CRYOPRESERVATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOPRESERVATION MARKET SIZE, BY CRYOPRESERVATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOPRESERVATION MARKET SIZE, BY HYPOTHERMIC STORAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOPRESERVATION MARKET SIZE, BY HYPOTHERMIC STORAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOPRESERVATION MARKET SIZE, BY HYPOTHERMIC STORAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOPRESERVATION MARKET SIZE, BY LYOPHILIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOPRESERVATION MARKET SIZE, BY LYOPHILIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOPRESERVATION MARKET SIZE, BY LYOPHILIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOPRESERVATION MARKET SIZE, BY VITRIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOPRESERVATION MARKET SIZE, BY VITRIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOPRESERVATION MARKET SIZE, BY VITRIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOPRESERVATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOPRESERVATION MARKET SIZE, BY BIOLOGICAL FLUIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOPRESERVATION MARKET SIZE, BY BIOLOGICAL FLUIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOPRESERVATION MARKET SIZE, BY BIOLOGICAL FLUIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOPRESERVATION MARKET SIZE, BY BLOOD COMPONENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOPRESERVATION MARKET SIZE, BY BLOOD COMPONENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOPRESERVATION MARKET SIZE, BY BLOOD COMPONENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOPRESERVATION MARKET SIZE, BY CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOPRESERVATION MARKET SIZE, BY CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOPRESERVATION MARKET SIZE, BY CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOPRESERVATION MARKET SIZE, BY ORGANS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOPRESERVATION MARKET SIZE, BY ORGANS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOPRESERVATION MARKET SIZE, BY ORGANS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOPRESERVATION MARKET SIZE, BY TISSUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOPRESERVATION MARKET SIZE, BY TISSUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOPRESERVATION MARKET SIZE, BY TISSUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOPRESERVATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOPRESERVATION MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOPRESERVATION MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOPRESERVATION MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOPRESERVATION MARKET SIZE, BY BLOOD PRESERVATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOPRESERVATION MARKET SIZE, BY BLOOD PRESERVATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOPRESERVATION MARKET SIZE, BY BLOOD PRESERVATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOPRESERVATION MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOPRESERVATION MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOPRESERVATION MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOPRESERVATION MARKET SIZE, BY ORGAN PRESERVATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOPRESERVATION MARKET SIZE, BY ORGAN PRESERVATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOPRESERVATION MARKET SIZE, BY ORGAN PRESERVATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOPRESERVATION MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOPRESERVATION MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOPRESERVATION MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOPRESERVATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOPRESERVATION MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOPRESERVATION MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOPRESERVATION MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOPRESERVATION MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOPRESERVATION MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOPRESERVATION MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOPRESERVATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOPRESERVATION MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOPRESERVATION MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOPRESERVATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOPRESERVATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOPRESERVATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIOPRESERVATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOPRESERVATION MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIOPRESERVATION MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOPRESERVATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS BIOPRESERVATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS BIOPRESERVATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS BIOPRESERVATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS BIOPRESERVATION MARKET SIZE, BY CRYOPROTECTANTS, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS BIOPRESERVATION MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS BIOPRESERVATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS BIOPRESERVATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS BIOPRESERVATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS BIOPRESERVATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA BIOPRESERVATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA BIOPRESERVATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA BIOPRESERVATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA BIOPRESERVATION MARKET SIZE, BY CRYOPROTECTANTS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA BIOPRESERVATION MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA BIOPRESERVATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA BIOPRESERVATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA BIOPRESERVATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA BIOPRESERVATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA BIOPRESERVATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA BIOPRESERVATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA BIOPRESERVATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA BIOPRESERVATION MARKET SIZE, BY CRYOPROTECTANTS, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA BIOPRESERVATION MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA BIOPRESERVATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA BIOPRESERVATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA BIOPRESERVATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA BIOPRESERVATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA BIOPRESERVATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA BIOPRESERVATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA BIOPRESERVATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA BIOPRESERVATION MARKET SIZE, BY CRYOPROTECTANTS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA BIOPRESERVATION MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA BIOPRESERVATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA BIOPRESERVATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA BIOPRESERVATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA BIOPRESERVATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE BIOPRESERVATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE BIOPRESERVATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE BIOPRESERVATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE BIOPRESERVATION MARKET SIZE, BY CRYOPROTECTANTS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE BIOPRESERVATION MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE BIOPRESERVATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE BIOPRESERVATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE BIOPRESERVATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE BIOPRESERVATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST BIOPRESERVATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST BIOPRESERVATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST BIOPRESERVATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST BIOPRESERVATION MARKET SIZE, BY CRYOPROTECTANTS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST BIOPRESERVATION MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST BIOPRESERVATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST BIOPRESERVATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST BIOPRESERVATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST BIOPRESERVATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA BIOPRESERVATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA BIOPRESERVATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA BIOPRESERVATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA BIOPRESERVATION MARKET SIZE, BY CRYOPROTECTANTS, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA BIOPRESERVATION MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA BIOPRESERVATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA BIOPRESERVATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA BIOPRESERVATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA BIOPRESERVATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC BIOPRESERVATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC BIOPRESERVATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC BIOPRESERVATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC BIOPRESERVATION MARKET SIZE, BY CRYOPROTECTANTS, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC BIOPRESERVATION MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC BIOPRESERVATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC BIOPRESERVATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC BIOPRESERVATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC BIOPRESERVATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL BIOPRESERVATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN BIOPRESERVATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN BIOPRESERVATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN BIOPRESERVATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN BIOPRESERVATION MARKET SIZE, BY CRYOPROTECTANTS, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN BIOPRESERVATION MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN BIOPRESERVATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN BIOPRESERVATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN BIOPRESERVATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN BIOPRESERVATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. GCC BIOPRESERVATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GCC BIOPRESERVATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. GCC BIOPRESERVATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 183. GCC BIOPRESERVATION MARKET SIZE, BY CRYOPROTECTANTS, 2018-2032 (USD MILLION)
  • TABLE 184. GCC BIOPRESERVATION MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 185. GCC BIOPRESERVATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. GCC BIOPRESERVATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC BIOPRESERVATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. GCC BIOPRESERVATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION BIOPRESERVATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION BIOPRESERVATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION BIOPRESERVATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION BIOPRESERVATION MARKET SIZE, BY CRYOPROTECTANTS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION BIOPRESERVATION MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION BIOPRESERVATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION BIOPRESERVATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION BIOPRESERVATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION BIOPRESERVATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS BIOPRESERVATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS BIOPRESERVATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS BIOPRESERVATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS BIOPRESERVATION MARKET SIZE, BY CRYOPROTECTANTS, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS BIOPRESERVATION MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS BIOPRESERVATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS BIOPRESERVATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS BIOPRESERVATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS BIOPRESERVATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. G7 BIOPRESERVATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. G7 BIOPRESERVATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 BIOPRESERVATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 210. G7 BIOPRESERVATION MARKET SIZE, BY CRYOPROTECTANTS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 BIOPRESERVATION MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 212. G7 BIOPRESERVATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. G7 BIOPRESERVATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. G7 BIOPRESERVATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. G7 BIOPRESERVATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. NATO BIOPRESERVATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. NATO BIOPRESERVATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. NATO BIOPRESERVATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 219. NATO BIOPRESERVATION MARKET SIZE, BY CRYOPROTECTANTS, 2018-2032 (USD MILLION)
  • TABLE 220. NATO BIOPRESERVATION MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 221. NATO BIOPRESERVATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. NATO BIOPRESERVATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. NATO BIOPRESERVATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. NATO BIOPRESERVATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL BIOPRESERVATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES BIOPRESERVATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES BIOPRESERVATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES BIOPRESERVATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES BIOPRESERVATION MARKET SIZE, BY CRYOPROTECTANTS, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES BIOPRESERVATION MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES BIOPRESERVATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES BIOPRESERVATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES BIOPRESERVATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES BIOPRESERVATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA BIOPRESERVATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA BIOPRESERVATION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA BIOPRESERVATION MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA BIOPRESERVATION MARKET SIZE, BY CRYOPROTECTANTS, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA BIOPRESERVATION MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA BIOPRESERVATION MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA BIOPRESERVATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA BIOPRESERVATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA BIOPRESERVATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)